45,391 results match your criteria advanced lung


A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.

Cancer Treat Res Commun 2021 Jun 9;28:100416. Epub 2021 Jun 9.

University of Washington, Department of Medicine, Division of Medical Oncology United States.

Background: Patients with metastatic non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation have effective targeted therapy options initially but most patients eventually progress and receive cytotoxic chemotherapy. In this single-institution phase II study, we evaluated the role of nab-paclitaxel monotherapy in this patient population.

Patients And Methods: Patients with metastatic NSCLC with an activating EGFR mutation whose disease progressed after frontline tyrosine kinase inhibitor therapy and who were chemotherapy naïve received nab-paclitaxel 125 mg/m2 on days 1, 8 and 15 in a 28-day cycle. Read More

View Article and Full-Text PDF

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

Lancet Oncol 2021 Jun 9. Epub 2021 Jun 9.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Oncogenic alterations in RET have been identified in multiple tumour types, including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC.

Methods: ARROW is a multi-cohort, open-label, phase 1/2 study done at 71 sites (community and academic cancer centres) in 13 countries (Belgium, China, France, Germany, Hong Kong, Italy, Netherlands, Singapore, South Korea, Spain, Taiwan, the UK, and the USA). Read More

View Article and Full-Text PDF

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Oncol Ther 2021 Jun 11. Epub 2021 Jun 11.

Programa de Pós-Graduação Em Medicamentos E Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Introduction: Lung cancer is the most frequently diagnosed type of cancer and the main cause of death from malignant neoplasms worldwide. One of the most recent discoveries in the context of non-small cell lung cancer (NSCLC) was the mutation of the anaplastic lymphoma kinase receptor (ALK). This genetic alteration is found in approximately 2-5% of NSCLC patients, and crizotinib was the first targeted therapy discovered for its first-line treatment. Read More

View Article and Full-Text PDF

CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.

Int J Clin Oncol 2021 Jun 11. Epub 2021 Jun 11.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka, 589-8511, Japan.

Background: We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M-positive non-small cell lung cancer (NSCLC).

Methods: The study included patients with EGFR activating mutation-positive advanced NSCLC who were positive for T790M in tumor tissue or plasma after previous treatment with an EGFR tyrosine kinase inhibitor, who received osimertinib at Kindai University Hospital between August 2014 and September 2017, and for whom plasma collected after progression on osimertinib was available. Clinical data were extracted from medical records. Read More

View Article and Full-Text PDF

Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.

J Thorac Oncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osakasayama, Japan.

Introduction: About 10% of locally-advanced non-small cell lung cancer (LA-NSCLC) patients harbor epidermal growth factor receptor (EGFR) mutation and recent reports suggested the declined benefit with immune-checkpoint inhibitor in this population. The attempt that introduces EGFR-tyrosine kinase inhibitor (TKI) into the treatment of LA-NSCLC with EGFR mutation has been warranted.

Methods: Chemotherapy-naïve, unresectable LA-NSCLC patients with sensitive EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were enrolled. Read More

View Article and Full-Text PDF

Diffeomorphic Respiratory Motion Estimation of Thoracoabdominal Organs for Image-Guided Interventions.

Med Phys 2021 Jun 11. Epub 2021 Jun 11.

Department of Mechanical Engineering and Automation, Harbin Institute of Technology, Shenzhen, 518055, China.

Purpose: Percutaneous image-guided interventions are commonly used for the diagnosis and treatment of cancer. In practice, physiological breathing-induced motion increases the difficulty of accurately inserting needles into tumors without impairing the surrounding vital structures. In this work, we propose a data-driven patient-specific hierarchical respiratory motion estimation framework to accurately estimate the position of a tumor and surrounding vital tissues in real time. Read More

View Article and Full-Text PDF

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.

Jpn J Clin Oncol 2021 Jun 12. Epub 2021 Jun 12.

Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

Background: In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer. Herein, we report the 2-year progression-free survival, overall survival and safety profile of these patients.

Methods: Chemo-naïve patients with EGFR-mutant advanced non-small-cell lung cancer were enrolled. Read More

View Article and Full-Text PDF

Trends in Endotracheal Intubation During In-Hospital Cardiac Arrests: 2001-2018.

Crit Care Med 2021 Jun 9. Epub 2021 Jun 9.

Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA. Center for the Study of Healthcare Innovation, Implementation, and Policy, Health Services Research and Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA. Center for Resuscitation Science, Department of Emergency Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Division of Hospital Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA. Division of Pulmonary, Critical Care Medicine, and Sleep Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Objectives: Airway management during in-hospital cardiac arrest represents a fundamental component of resuscitative efforts, yet little is known about temporal trends in intubation during in-hospital cardiac arrest. Our objective was to investigate changes in in-hospital cardiac arrest airway management over time and in response to national guideline updates.

Design: Observational cohort study of a prospectively collected database. Read More

View Article and Full-Text PDF

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.

J Natl Cancer Inst 2021 Jun 11. Epub 2021 Jun 11.

Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, 677 Huntington Ave, Boston, MA, USA.

Background: Despite the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in a subset of patients, consistent and easily obtainable predictors of efficacy remain elusive.

Methods: This study was conducted on 644 advanced non-small cell lung cancer (NSCLC) patients treated with ICI monotherapy between April 2013 and September 2020 at the Dana-Farber Cancer Institute and Brigham and Women's Hospital. Patient smoking history, clinicopathological characteristics, tumor mutation burden (TMB) by clinical targeted next generation sequencing, and PD-L1 tumor proportion score (TPS) by immunohistochemistry were prospectively collected. Read More

View Article and Full-Text PDF

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.

Medicine (Baltimore) 2021 Jun;100(23):e25774

Division of Medical Oncology, Department of Medicine, Showa University School of Medicine.

Introduction: Immune checkpoint inhibitors (ICIs), particularly anti-PD-1 antibody, have dramatically changed cancer treatment; however, fatal immune-related adverse events (irAEs) can develop. Here, we describe a severe case of sclerosing cholangitis-like irAE. We report the use of 3 immunosuppressive agents that resulted in the death of the patient due to treatment inefficacy. Read More

View Article and Full-Text PDF

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety.

Medicine (Baltimore) 2021 Jun;100(23):e25709

People's Hospital of Changxing, Huzhou, Zhejiang, China.

Purpose: In this meta-analysis and systemic review, we focused on the effectiveness and safety of anlotinib in patients with advanced non-small cell lung cancer(NSCLC).

Methods: The databases of PubMed, EMBASE, Cochrane Library, CNKI, Wanfang, and CBM were searched by 2 investigators up to April 2020. Titles and abstracts of all records were screened and eligible publications were retrieved in full. Read More

View Article and Full-Text PDF

Radiogenomic Analysis of Locally Advanced Lung Cancer Based on CT Imaging and Intratreatment Changes in Cell-Free DNA.

Radiol Imaging Cancer 2021 Apr;3(4):e200157

From the Departments of Radiation Oncology (K.J.L., M.N.C., C.D.J., J.W., Y.C., C.W., C.R.K., F.F.Y.), Radiology (K.J.L.), Biostatistics and Bioinformatics (J.G.), and Medicine (A.H.), Duke University School of Medicine, 2301 Erwin Rd, Durham, NC 27710; Department of Electrical and Computer Engineering, Duke University Pratt School of Engineering, Durham, NC (K.J.L.); Radiology Medical Group of Napa, Napa, Calif (M.N.C.); Department of Radiation Oncology, Columbia University School of Medicine, New York, NY (E.X.); and Inivata, Cambridge, England (G.J.).

The radiologic appearance of locally advanced lung cancer may be linked to molecular changes of the disease during treatment, but characteristics of this phenomenon are poorly understood. Radiomics, liquid biopsy of cell-free DNA (cfDNA), and next-generation sequencing of circulating tumor DNA (ctDNA) encode tumor-specific radiogenomic expression patterns that can be probed to study this problem. Preliminary findings are reported from a radiogenomic analysis of CT imaging, cfDNA, and ctDNA in 24 patients (median age, 64 years; range, 49-74 years) with stage III lung cancer undergoing chemoradiation on a prospective pilot study (NCT00921739) between September 2009 and September 2014. Read More

View Article and Full-Text PDF

Anticancer activity of indapamide adsorbed on gold nanoparticles: DFT, in-silico, and in-vitro analysis.

J Mol Recognit 2021 Jun 11:e2920. Epub 2021 Jun 11.

Centre for Advanced Functional Materials, Department of Physics, Bishop Moore College, Mavelikara, Kerala, 690110, India.

The adsorption properties of the lung cancer agent indapamide (IND) on gold nanoparticles (AuNPs), were studied with the help of surface-enhanced Raman scattering techniques. The structure-activity of the IND and INDA molecule has been studied using DFT/B3LYP methodology. NBO analysis reveals that, both the molecules are stabilized by a C─H O intramolecular hydrogen bonding, apart from the conjugative and intramolecular charge transfer interactions. Read More

View Article and Full-Text PDF

Multiple Pulmonary Metastases of Recurrent Giant Cell Tumor of Bone with Expression of VEGFR-2 Successfully Controlled by Denosumab and Apatinib: A Case Report and Literature Review.

Cancer Manag Res 2021 3;13:4447-4454. Epub 2021 Jun 3.

Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.

Giant cell tumor of bone (GCTB) is a rare, benign, but locally aggressive bone tumor. It has a high tendency for local recurrence, which may increase the incidence of lung metastasis. Currently, an optimal treatment strategy has not been established because of the rarity of pulmonary metastatic GCTB. Read More

View Article and Full-Text PDF

IgA Vasculitis in a Lung Cancer Patient During Chemoradiotherapy.

Ther Clin Risk Manag 2021 3;17:571-575. Epub 2021 Jun 3.

Department of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.

A 72-year-old man with locally advanced lung squamous cell carcinoma experienced red purpura on the lower legs and hematuria when the disease progressed during definitive chemoradiotherapy. He had renal dysfunction and proteinuria. Biopsy specimens of the skin lesion and kidney revealed immunoglobulin A vasculitis. Read More

View Article and Full-Text PDF

LncRNA CTD-2528L19.6 prevents the progression of IPF by alleviating fibroblast activation.

Cell Death Dis 2021 Jun 10;12(6):600. Epub 2021 Jun 10.

Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China.

Long non-coding RNAs (lncRNAs) have emerged as critical factors for regulating multiple biological processes during organ fibrosis. However, the mechanism of lncRNAs in idiopathic pulmonary fibrosis (IPF) remains incompletely understood. In the present study, two sets of lncRNAs were defined: IPF pathogenic lncRNAs and IPF progression lncRNAs. Read More

View Article and Full-Text PDF

Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.

BMC Cancer 2021 Jun 10;21(1):689. Epub 2021 Jun 10.

Hospital Universitario Fundacion Jimenez Diaz - CIBERONC, Madrid, Spain.

Background: Currently biomarkers play an essential role in diagnosis, treatment, and management of cancer. In non-small cell lung cancer (NSCLC) determination of biomarkers such as ALK, EGFR, ROS1 or PD-L1 is mandatory for an adequate treatment decision. The aim of this study is to determine the clinical and economic impact of current anaplastic lymphoma kinase testing scenario in Spain. Read More

View Article and Full-Text PDF

Two autopsy cases with injuries to the stomach following cardiopulmonary resuscitation.

Leg Med (Tokyo) 2021 Jun 4;53:101916. Epub 2021 Jun 4.

Department of Legal Medicine, Faculty of Medicine, University of Toyama, Toyama, Japan. Electronic address:

We herein report two autopsy cases with gastric injury associated with cardiopulmonary resuscitation (CPR). Case 1 was a 36-year-old woman who was found in cardiopulmonary arrest possibly caused by a fall from a height of 8 m. She received continuous manual chest compression with artificial ventilation while being transferred to the hospital. Read More

View Article and Full-Text PDF

Venoarterial Extracorporeal Membrane Oxygenator Support in Lung Cancer Resection.

Ann Thorac Surg 2021 Jun 7. Epub 2021 Jun 7.

Department of Thoracic Surgery, IRCCS San Raffaele Scientific Institute, Milan, Italy; Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy. Electronic address:

Cardiovascular comorbidities often prevent patients with otherwise resectable early-stage lung cancer from undergoing surgery due to prohibitive peri-operative risk. Here we describe the first intraoperative use of venoarterial (VA) ECMO in a stage cIIA lung cancer patient with arterial infiltration and severe post-ischemic dilated cardiomyopathy (EF 23%) undergoing left upper lobectomy with pulmonary artery angioplasty. Providing intra-operative cardiovascular and respiratory function support, VA-ECMO represents a suitable option for patients with heart failure, ensuring adequate hemodynamic profile and reducing the risk of complications. Read More

View Article and Full-Text PDF

Trapezial Acrometastasis as the First Presentation of Occult Lung Cancer: A Case Report.

JBJS Case Connect 2021 06 10;11(2). Epub 2021 Jun 10.

Orthopedic Specialists of Central Pennsylvania, Lancaster, Pennsylvania.

Case: Acrometastasis is extremely rare, accounting for 0.1% of all skeletal metastases. Metastases to the carpus are rarer still. Read More

View Article and Full-Text PDF

Inflammation, Infection and Venous Thromboembolism.

Circ Res 2021 Jun 10;128(12):2017-2036. Epub 2021 Jun 10.

Laboratory of Vascular Thrombosis and Inflammation, Intramural Research Program (Y.K.), National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

The association between inflammation, infection, and venous thrombosis has long been recognized; yet, only in the last decades have we begun to understand the mechanisms through which the immune and coagulation systems interact and reciprocally regulate one another. These interconnected networks mount an effective response to injury and pathogen invasion, but if unregulated can result in pathological thrombosis and organ damage. Neutrophils, monocytes, and platelets interact with each other and the endothelium in host defense and also play critical roles in the formation of venous thromboembolism. Read More

View Article and Full-Text PDF

Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments.

Curr Treat Options Oncol 2021 Jun 10;22(8):71. Epub 2021 Jun 10.

Osaka Prefectural Hospital Organization, Osaka International Cancer Institute, Department of Medical Check-up, Osaka, Japan.

Opinion Statement: Lung cancer is the most common form of cancer in humans and the leading cause of cancer-related death worldwide. Traditionally, lung cancer has been diagnosed as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). However, recent developments in molecular pathology have revolutionized the diagnosis and treatment of the disease, thus improving patient prognosis and increasing the number of survivors. Read More

View Article and Full-Text PDF

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.

Curr Treat Options Oncol 2021 Jun 10;22(8):69. Epub 2021 Jun 10.

Clinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, Via Conca 71, 60126, Ancona, Italy.

Opinion Statement: Advanced colorectal cancer (CRC) is a heterogeneous disease, characterized by several subtypes with distinctive genetic and epigenetic patterns. During the last years, immune checkpoint inhibitors (ICIs) have revamped the standard of care of several tumors such as non-small cell lung cancer and melanoma, highlighting the role of immune cells in tumor microenvironment (TME) and their impact on cancer progression and treatment efficacy. An "immunoscore," based on the percentage of two lymphocyte populations both at tumor core and invasive margin, has been shown to improve prediction of treatment outcome when added to UICC-TNM classification. Read More

View Article and Full-Text PDF

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1 and BCR-ABL1.

Ann Hematol 2021 Jun 10. Epub 2021 Jun 10.

Department of Nutrition and Natural Products, Migal-Galilee Technology Center, PO Box 831, 11016, Kiryat Shmona, Israel.

Resistance remains the major clinical challenge for the therapy of Philadelphia chromosome-positive (Ph+) leukemia. With the exception of ponatinib, all approved tyrosine kinase inhibitors (TKIs) are unable to inhibit the common "gatekeeper" mutation T315I. Here we investigated the therapeutic potential of crizotinib, a TKI approved for targeting ALK and ROS1 in non-small cell lung cancer patients, which inhibited also the ABL1 kinase in cell-free systems, for the treatment of advanced and therapy-resistant Ph+ leukemia. Read More

View Article and Full-Text PDF

[Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer].

Strahlenther Onkol 2021 Jun 10. Epub 2021 Jun 10.

Klinik für Strahlentherapie, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Feldstr. 21, 24105, Kiel, Deutschland.

View Article and Full-Text PDF

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as mortality predictor of advanced stage non-small cell lung cancer (NSCLC) with COVID-19 in Indonesia.

Eur Rev Med Pharmacol Sci 2021 05;25(10):3868-3878

Lung Cancer Teamwork, Department of Medical Hematology-Oncology, Dharmais National Cancer Center, Jakarta, Indonesia.

Objective: This study aimed to compare the mortality rate between advanced-stage non-small cell lung cancer patients (NSCLC) with and without COVID-19. This study also explores the possible laboratory characteristics used for prognostication in patients with NSCLC and COVID-19. Additionally, this study evaluated potential differences in laboratory values between the case and control groups. Read More

View Article and Full-Text PDF

Molecular Identification and Genetic Characterization of Early-Stage Multiple Primary Lung Cancer by Large-Panel Next-Generation Sequencing Analysis.

Front Oncol 2021 24;11:653988. Epub 2021 May 24.

Department of Thoracic Surgery, Beijing Haidian Hospital, Beijing, China.

Objective: The incidence of early stage multiple primary lung cancer (MPLC) has been increasing in recent years, while the ideal strategy for its diagnosis and treatment remains controversial. The present study conducted genomic analysis to identify a new molecular classification method for accurately predicting the diagnosis and therapy for patients with early stage MPLC.

Methods: A total of 240 tissue samples from 203 patients with multiple-non-small-cell lung cancers (NSCLCs) (n = 30), early stage single-NSCLC (Group A, n = 94), and advanced-stage NSCLC (Group B, n = 79) were subjected to targeted multigene panel sequencing. Read More

View Article and Full-Text PDF

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer.

Front Oncol 2021 24;11:608608. Epub 2021 May 24.

Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.

Purpose: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been indicated to be an effective treatment for advanced EGFR-mutant NSCLC. However, the neoadjuvant application of EGFR-TKIs in resectable NSCLC needs further investigation. Here, we aimed to evaluate the efficacy and safety of neoadjuvant EGFR-TKIs for lung cancer. Read More

View Article and Full-Text PDF

Endogenous agonist-bound S1PR3 structure reveals determinants of G protein-subtype bias.

Sci Adv 2021 Jun 9;7(24). Epub 2021 Jun 9.

Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.

Sphingosine-1-phosphate (S1P) regulates numerous important physiological functions, including immune response and vascular integrity, via its cognate receptors (S1PR1 to S1PR5); however, it remains unclear how S1P activates S1PRs upon binding. Here, we determined the crystal structure of the active human S1PR3 in complex with its natural agonist S1P at 3.2-Å resolution. Read More

View Article and Full-Text PDF